Tissue inhibitor of metalloproteinase 1 promotes ferroptosis and suppresses prostate cancer metastasis

作者：Y. K. Rao, Qi Pan, Siyu Liu, Shunheng Yao, Lei Li, Jianyan Yan, Lifen Chen, Li Xu, Yan Han, Aicui Ma, Fen Wang, Xiaoyan Mao, Zhonghui Wang, Junfang Zhang, Jun Guo, Zuyue Sun · 发表于：Journal of Biological Chemistry · 年份：2025 · DOI：10.1016/j.jbc.2025.108473 · 被引用次数：3 · 研究领域：Ferroptosis and cancer prognosis、Cancer, Lipids, and Metabolism、RNA modifications and cancer

Tissue inhibitor of metalloproteinase 1 (TIMP1) has been implicated in prostate cancer (PCa) metastasis. In this study, PC-3M-2B4 cells with TIMP1 knockdown (PC-3M-2B4-shTIMP1) or overexpression (PC-3M-2B4-TIMP1) were generated, and an inverse correlation was found between TIMP1 expression and cell migration and invasion, which was confirmed in vitro and in vivo . Differential TIMP1 expression was accompanied by variations in the expression of the ferroptosis-related proteins, glutathione peroxidase 4 (GPX4), transferrin receptor, transferrin, glutamine cysteine ligase catalytic subunit, and glutamine cysteine ligase modifier subunit. In comparison with TIMP1-overexpressing cells, TIMP1-knockdown cells demonstrated a 12.3% decrease in Fe 2+ concentration after erastin treatment, a 37.8% reduction in malondialdehyde levels, an 113.7% increase in GPX4 expression, and a 78.9% rise in the GSH–GSSG ratio. Our findings indicate that TIMP1 overexpression promotes ferroptosis by modulating critical markers, such as GPX4 and transferrin receptor, thereby significantly reducing metastatic potential in PCa cells. Our results highlight the role of TIMP1 in regulating ferroptosis pathways, which are crucial for tumor progression, and exposes a potential therapeutic target for PCa management.